Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk

trastuzumab  Trastuzumab exerts an antitumour activity and is used in the treatment of HER2-positive breast cancer HER2 protein overexpression is observed in 20%-30% of Trastuzumab was developed by Genentech Inc as a recombinant humanized monoclonal antibody directed against the

Key Message The ShortHER trial failed to demonstrate the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy The short Trastuzumab was developed by Genentech Inc as a recombinant humanized monoclonal antibody directed against the

Trastuzumab deruxtecan Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal ต้นทุนประสิทธิผลของการใช้ Trastuzumab ร่วมลำดับแรกในมะเร็งเต้านมระยะแพร่กระจายที่ HER2 ให้ผลบวก สุพล ลิมวัฒนานนท์, จุฬาภรณ์ ลิมวัฒนานนท์, สาวิตรี เมาฬีกุลไพโรจน์, เอื้อมแข สุขประเสริฐ, นพดล